NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP EBITDA Margin

EBITDA as a percentage of revenue.

NovaBridge BiosciencesNASDAQ: NBP

EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025

EBITDA Margin not reported for Q4 FY2025

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2025
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-7674.2%
Year-over-year change
-8153.1pp

EBITDA Margin vs competitors

How NBP compares with its peers on the latest reported figures

NBP Competitors Peer median
EBITDA Margin for NBP and competitors
Company Period LTM level YoY 3-year change
ALTAltimmune, Inc.LTM Mar 2026-245200.0% +208560.0 pp-336389.4 pp
NBPNovaBridge BiosciencesFY2025— ——
LBRXLB Pharmaceuticals Inc Common StockFY2025— ——
DRTSAlpha Tau Medical Ltd.FY2025— ——
AURAAura Biosciences, Inc.FY2025— ——
DSGNDesign Therapeutics, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
DMACDiaMedica Therapeutics Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
GALTGalectin Therapeutics Inc.FY2025— ——
ENGNenGene Holdings Inc.FY2025— ——
Peer median (excluding NBP) -245200.0%+208560.0 pp-336389.4 pp

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.